Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line

Joseph B. Moore, David M. Loeb, Kyung U. Hong, Poul H. Sorensen, Timothy J. Triche, David W. Lee, Michael I. Barbato, Robert J. Arceci

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Developmental reprogramming techniques have been used to generate induced pluripotent stem (iPS) cells from both normal and malignant cells. The derivation of iPS cells from cancer has the potential to provide a unique scientific tool to overcome challenges associated with the establishment of cell lines from primary patient samples and a readily expandable source of cells that may be used to model the initial disease. In the current study we developmentally reprogrammed a metastatic Ewing sarcoma (EWS) cell line to a meta-stable embryonic stem (ES)-like state sharing molecular and phenotypic features with previously established ES and iPS cell lines. EWS-iPS cells exhibited a pronounced drug resistant phenotype despite persistent expression of the oncogenic EWS-FLI1 fusion transcript. This included resistance to compounds that specifically target downstream effector pathways of EWS-FLI1, such as MAPK/ERK and PI3K/AKT, which play an important role in EWS pathogenesis. EWS-iPS cells displayed tumor initiation abilities in vivo and formed tumors exhibiting characteristic Ewing histopathology. In parallel, EWS-iPS cells re-differentiated in vitro recovered sensitivity to molecularly targeted chemotherapeutic agents, which reiterated pathophysiological features of the cells from which they were derived. These data suggest that EWS-iPS cells may provide an expandable disease model that could be used to investigate processes modulating oncogenesis, metastasis, and chemotherapeutic resistance in EWS.

Original languageEnglish (US)
Article number15
JournalFrontiers in Cell and Developmental Biology
Volume3
Issue numberMAR
DOIs
StatePublished - Mar 9 2015
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Induced Pluripotent Stem Cells
Epigenomics
Cell Line
Neoplasms
Phosphatidylinositol 3-Kinases
Carcinogenesis
Neoplasm Metastasis
Phenotype

Keywords

  • Drug resistance
  • Epigenetics
  • Ewing sarcoma
  • Induced pluripotent stem cells
  • Reprogramming

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Moore, J. B., Loeb, D. M., Hong, K. U., Sorensen, P. H., Triche, T. J., Lee, D. W., ... Arceci, R. J. (2015). Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line. Frontiers in Cell and Developmental Biology, 3(MAR), [15]. https://doi.org/10.3389/fcell.2015.00015

Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line. / Moore, Joseph B.; Loeb, David M.; Hong, Kyung U.; Sorensen, Poul H.; Triche, Timothy J.; Lee, David W.; Barbato, Michael I.; Arceci, Robert J.

In: Frontiers in Cell and Developmental Biology, Vol. 3, No. MAR, 15, 09.03.2015.

Research output: Contribution to journalArticle

Moore, JB, Loeb, DM, Hong, KU, Sorensen, PH, Triche, TJ, Lee, DW, Barbato, MI & Arceci, RJ 2015, 'Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line', Frontiers in Cell and Developmental Biology, vol. 3, no. MAR, 15. https://doi.org/10.3389/fcell.2015.00015
Moore, Joseph B. ; Loeb, David M. ; Hong, Kyung U. ; Sorensen, Poul H. ; Triche, Timothy J. ; Lee, David W. ; Barbato, Michael I. ; Arceci, Robert J. / Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line. In: Frontiers in Cell and Developmental Biology. 2015 ; Vol. 3, No. MAR.
@article{003e4052831e4aa0b61a6448454eeb32,
title = "Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line",
abstract = "Developmental reprogramming techniques have been used to generate induced pluripotent stem (iPS) cells from both normal and malignant cells. The derivation of iPS cells from cancer has the potential to provide a unique scientific tool to overcome challenges associated with the establishment of cell lines from primary patient samples and a readily expandable source of cells that may be used to model the initial disease. In the current study we developmentally reprogrammed a metastatic Ewing sarcoma (EWS) cell line to a meta-stable embryonic stem (ES)-like state sharing molecular and phenotypic features with previously established ES and iPS cell lines. EWS-iPS cells exhibited a pronounced drug resistant phenotype despite persistent expression of the oncogenic EWS-FLI1 fusion transcript. This included resistance to compounds that specifically target downstream effector pathways of EWS-FLI1, such as MAPK/ERK and PI3K/AKT, which play an important role in EWS pathogenesis. EWS-iPS cells displayed tumor initiation abilities in vivo and formed tumors exhibiting characteristic Ewing histopathology. In parallel, EWS-iPS cells re-differentiated in vitro recovered sensitivity to molecularly targeted chemotherapeutic agents, which reiterated pathophysiological features of the cells from which they were derived. These data suggest that EWS-iPS cells may provide an expandable disease model that could be used to investigate processes modulating oncogenesis, metastasis, and chemotherapeutic resistance in EWS.",
keywords = "Drug resistance, Epigenetics, Ewing sarcoma, Induced pluripotent stem cells, Reprogramming",
author = "Moore, {Joseph B.} and Loeb, {David M.} and Hong, {Kyung U.} and Sorensen, {Poul H.} and Triche, {Timothy J.} and Lee, {David W.} and Barbato, {Michael I.} and Arceci, {Robert J.}",
year = "2015",
month = "3",
day = "9",
doi = "10.3389/fcell.2015.00015",
language = "English (US)",
volume = "3",
journal = "Frontiers in Cell and Developmental Biology",
issn = "2296-634X",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line

AU - Moore, Joseph B.

AU - Loeb, David M.

AU - Hong, Kyung U.

AU - Sorensen, Poul H.

AU - Triche, Timothy J.

AU - Lee, David W.

AU - Barbato, Michael I.

AU - Arceci, Robert J.

PY - 2015/3/9

Y1 - 2015/3/9

N2 - Developmental reprogramming techniques have been used to generate induced pluripotent stem (iPS) cells from both normal and malignant cells. The derivation of iPS cells from cancer has the potential to provide a unique scientific tool to overcome challenges associated with the establishment of cell lines from primary patient samples and a readily expandable source of cells that may be used to model the initial disease. In the current study we developmentally reprogrammed a metastatic Ewing sarcoma (EWS) cell line to a meta-stable embryonic stem (ES)-like state sharing molecular and phenotypic features with previously established ES and iPS cell lines. EWS-iPS cells exhibited a pronounced drug resistant phenotype despite persistent expression of the oncogenic EWS-FLI1 fusion transcript. This included resistance to compounds that specifically target downstream effector pathways of EWS-FLI1, such as MAPK/ERK and PI3K/AKT, which play an important role in EWS pathogenesis. EWS-iPS cells displayed tumor initiation abilities in vivo and formed tumors exhibiting characteristic Ewing histopathology. In parallel, EWS-iPS cells re-differentiated in vitro recovered sensitivity to molecularly targeted chemotherapeutic agents, which reiterated pathophysiological features of the cells from which they were derived. These data suggest that EWS-iPS cells may provide an expandable disease model that could be used to investigate processes modulating oncogenesis, metastasis, and chemotherapeutic resistance in EWS.

AB - Developmental reprogramming techniques have been used to generate induced pluripotent stem (iPS) cells from both normal and malignant cells. The derivation of iPS cells from cancer has the potential to provide a unique scientific tool to overcome challenges associated with the establishment of cell lines from primary patient samples and a readily expandable source of cells that may be used to model the initial disease. In the current study we developmentally reprogrammed a metastatic Ewing sarcoma (EWS) cell line to a meta-stable embryonic stem (ES)-like state sharing molecular and phenotypic features with previously established ES and iPS cell lines. EWS-iPS cells exhibited a pronounced drug resistant phenotype despite persistent expression of the oncogenic EWS-FLI1 fusion transcript. This included resistance to compounds that specifically target downstream effector pathways of EWS-FLI1, such as MAPK/ERK and PI3K/AKT, which play an important role in EWS pathogenesis. EWS-iPS cells displayed tumor initiation abilities in vivo and formed tumors exhibiting characteristic Ewing histopathology. In parallel, EWS-iPS cells re-differentiated in vitro recovered sensitivity to molecularly targeted chemotherapeutic agents, which reiterated pathophysiological features of the cells from which they were derived. These data suggest that EWS-iPS cells may provide an expandable disease model that could be used to investigate processes modulating oncogenesis, metastasis, and chemotherapeutic resistance in EWS.

KW - Drug resistance

KW - Epigenetics

KW - Ewing sarcoma

KW - Induced pluripotent stem cells

KW - Reprogramming

UR - http://www.scopus.com/inward/record.url?scp=84938934272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938934272&partnerID=8YFLogxK

U2 - 10.3389/fcell.2015.00015

DO - 10.3389/fcell.2015.00015

M3 - Article

AN - SCOPUS:84938934272

VL - 3

JO - Frontiers in Cell and Developmental Biology

JF - Frontiers in Cell and Developmental Biology

SN - 2296-634X

IS - MAR

M1 - 15

ER -